Cargando…

Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial

BACKGROUND: Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, internationa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singer, Daniel E., Hellkamp, Anne S., Piccini, Jonathan P., Mahaffey, Kenneth W., Lokhnygina, Yuliya, Pan, Guohua, Halperin, Jonathan L., Becker, Richard C., Breithardt, Günter, Hankey, Graeme J., Hacke, Werner, Nessel, Christopher C., Patel, Manesh R., Califf, Robert M., Fox, Keith A. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603243/ https://www.ncbi.nlm.nih.gov/pubmed/23525418 http://dx.doi.org/10.1161/JAHA.112.000067

Ejemplares similares

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
por: Singer, Daniel E., et al.
Publicado: (2015)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
por: Breithardt, Günter, et al.
Publicado: (2014)

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016)

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
por: Carnicelli, Anthony P., et al.
Publicado: (2021)

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
por: Quinn, Gene R., et al.
Publicado: (2018)

Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
por: Ugowe, Francis E., et al.
Publicado: (2021)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF
por: Ungar, Leo, et al.
Publicado: (2019)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
por: Pokorney, Sean D., et al.
Publicado: (2016)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Management of acute stroke in patients taking novel oral anticoagulants
por: Hankey, Graeme J, et al.
Publicado: (2014)

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
por: Perino, Alexander C., et al.
Publicado: (2019)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin: One-year follow-up
por: Zhuang, Liying, et al.
Publicado: (2022)

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT‐AF and PREVAIL Studies
por: Brouwer, Tom F., et al.
Publicado: (2019)

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
por: Jackson, Larry R., et al.
Publicado: (2018)

Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry
por: O'Brien, Emily C., et al.
Publicado: (2016)

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
por: Fox, Keith A A, et al.
Publicado: (2017)

Make : Rockets : down-to-earth rocket science
por: Westerfield, Mike
Publicado: (2014)

Rocketing into the future: the history and technology of rocket planes
por: van Pelt, Michel
Publicado: (2012)

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
por: Steinberg, Benjamin A., et al.
Publicado: (2018)

It is rocket science, then
por: Cookson, C
Publicado: (2003)

Rockets and missiles
por: Taylor, John W R
Publicado: (1970)

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Graves' Disease and Treatment Effects on Warfarin Anticoagulation
por: Howard-Thompson, Amanda, et al.
Publicado: (2014)

Beyond warfarin: The advent of new oral anticoagulants
por: Laroia, Sandeep T, et al.
Publicado: (2015)

Beyond warfarin: The advent of new oral anticoagulants
por: Malhotra, Konark, et al.
Publicado: (2016)

Piperine Alters the Pharmacokinetics and Anticoagulation of Warfarin in Rats
por: Zayed, Aref, et al.
Publicado: (2020)

Quality of anticoagulation with warfarin in rural Chhattisgarh, India
por: Chebrolu, Puja, et al.
Publicado: (2020)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h6phsve6k4kan03bubqeflu521